Stockreport

Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF NEW YORK and MELBOURNE, Australia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the f [Read more]